Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.